Puma Biotechnology Inc. Stock
€3.62
Your prediction
Puma Biotechnology Inc. Stock
Puma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Pros and Cons of Puma Biotechnology Inc. in the next few years
Pros
Cons
Performance of Puma Biotechnology Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Puma Biotechnology Inc. | 9.480% | 10.036% | 29.585% | 19.603% | -7.350% | -47.275% | - |
Ardelyx Inc. | 0.400% | -6.042% | -11.918% | 60.952% | -12.284% | 211.043% | - |
Evolus Inc | 1.890% | 1.887% | 10.204% | 64.885% | 19.337% | 13.089% | - |
Coherus Bioscien. | -1.880% | -0.956% | -2.907% | -61.062% | -50.559% | -86.459% | -90.599% |
News
![Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN29sRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2c39f3b6129a12541932c63b90c23307b141ad6b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/puma_logo_JPEG.jpg?locale=us)
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN29sRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2c39f3b6129a12541932c63b90c23307b141ad6b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/puma_logo_JPEG.jpg?locale=us)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN29sRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2c39f3b6129a12541932c63b90c23307b141ad6b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/puma_logo_JPEG.jpg?locale=us)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 6, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement